BioWorld

Aug. 28, 2003

AM1241, A Synthetic Compound, Activates Cannabinoid Painkiller, Proven In Rat, Mice Experiments

IPO Trend Hasn't Fizzled As TolerRx Plans $75M Offering

BioCryst Quits 3-Dimensional Deal To Spend Funds Elsewhere

Nymox Raises $12M Privately To Provide Three Years' Cash

Other News To Note

Flamel Finds New Basulin Partner, Signs $165M Bristol-Myers Deal

Flamel Technologies SA again has partnered its recombinant human insulin product, Basulin; this time, signing a deal with Bristol-Myers Squibb Co. valued at up to $165 million. (BioWorld Today) Read More

Metabolex Privately Raises $27M For MBX-102 Phase II Program

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...